UR-1102

a renal urate transporter 1 (URAT1) inhibitor with uricosuric acitivity; structure in first source

Also Known As:

(3,5-dibromo-4-hydroxyphenyl)(2,3-dihydro-4H-pyrido(4,3-b)(1,4)oxazin-4-yl)methanone

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Gout 04/01/2016 - "These results indicate that UR-1102 achieves strong uricosuric effects by selectively inhibiting URAT1 over OAT1 and OAT3 in monkeys, and could be a novel therapeutic option for patients with gout or hyperuricemia. " 01/01/2021 - "UR-1102, a novel uricosuric agent for treating gout, has been confirmed to exhibit a pharmacological effect in patients. " 01/01/2021 - "Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout."
2.	Hyperuricemia 04/01/2016 - "These results indicate that UR-1102 achieves strong uricosuric effects by selectively inhibiting URAT1 over OAT1 and OAT3 in monkeys, and could be a novel therapeutic option for patients with gout or hyperuricemia. "